CL2008001124A1 - Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. - Google Patents
Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.Info
- Publication number
- CL2008001124A1 CL2008001124A1 CL2008001124A CL2008001124A CL2008001124A1 CL 2008001124 A1 CL2008001124 A1 CL 2008001124A1 CL 2008001124 A CL2008001124 A CL 2008001124A CL 2008001124 A CL2008001124 A CL 2008001124A CL 2008001124 A1 CL2008001124 A1 CL 2008001124A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- useful
- treatment
- acid derivative
- pharmaceutical formulation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 title abstract 2
- 150000002500 ions Chemical class 0.000 title abstract 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical class [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91260507P | 2007-04-18 | 2007-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008001124A1 true CL2008001124A1 (es) | 2009-01-02 |
Family
ID=39872894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008001124A CL2008001124A1 (es) | 2007-04-18 | 2008-04-18 | Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. |
Country Status (19)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0810660A2 (pt) * | 2007-04-18 | 2014-10-07 | Cornerstone Pharmaceuticals Inc | Derivados do ácido lipóico |
| NZ580973A (en) | 2007-04-18 | 2011-10-28 | Cornerstone Pharmaceuticals Inc | Pharmaceutical formulations containing lipoic acid derivatives |
| US8263653B2 (en) | 2007-04-18 | 2012-09-11 | Cornerstone Pharmaceuticals, Inc. | Pharmaceutical formulations containing lipoic acid derivatives |
| EP2260019A4 (en) * | 2008-03-04 | 2011-08-03 | Shorr Robert | MODULATION OF ENZYMATIC STRUCTURE, ACTIVITY AND / OR EXPRESSION LEVEL |
| KR20110025168A (ko) * | 2008-04-04 | 2011-03-09 | 로버트 쇼어 | 약학적 조성물 |
| EP2389178A4 (en) * | 2008-12-01 | 2012-06-06 | Invasc Therapeutic Inc | COMPOSITIONS CONTAINING INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND LIPOIC ACID COMPOUNDS, AND THEIR USE FOR THE TREATMENT OF RENIN-ANGIOTENSIN-ALDOSTERONE ASSOCIATED DISORDERS |
| WO2010110771A2 (en) * | 2009-03-25 | 2010-09-30 | Frank Gibson | Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| WO2011143590A1 (en) * | 2010-05-14 | 2011-11-17 | Cornerstone Pharmaceuticals, Inc. | Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent |
| WO2011143593A1 (en) * | 2010-05-14 | 2011-11-17 | Cornerstone Pharmaceuticals, Inc. | Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof |
| EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| CN102657606B (zh) * | 2012-05-25 | 2014-01-01 | 江苏神龙药业有限公司 | 一种供静脉给药用的硫辛酸注射液 |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| CN105142643B (zh) * | 2012-12-19 | 2021-09-03 | 基石医药公司 | 药物化合物 |
| LT2968586T (lt) | 2013-03-14 | 2018-11-26 | Translate Bio, Inc. | Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai |
| TR201901310T4 (tr) | 2013-03-14 | 2019-02-21 | Translate Bio Inc | Mesajcı RNA'nın saflaştırılması yöntemleri. |
| CN103360437B (zh) * | 2013-04-27 | 2015-10-21 | 江苏教育学院 | 一种硫辛酸糖类衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
| CN103497344B (zh) * | 2013-09-25 | 2015-09-23 | 深圳先进技术研究院 | 用于负载贵金属颗粒的纳米凝胶及其制备方法与应用 |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| KR102739894B1 (ko) | 2014-04-25 | 2024-12-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| CA2965963A1 (en) * | 2014-06-19 | 2015-12-23 | Robert Shorr | Lipoic acid derivatives for pharmaceutical use |
| ES2747702T3 (es) | 2014-06-19 | 2020-03-11 | Rafael Pharmaceuticals Inc | Compuestos farmacéuticos |
| EP3585417B1 (en) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Method of making a codon-optimized cftr mrna |
| CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| CA3120647A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
| TW202114651A (zh) * | 2019-08-16 | 2021-04-16 | 美商拉斐爾製藥公司 | 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物 |
| WO2021174135A1 (en) * | 2020-02-28 | 2021-09-02 | University Of Florida Research Foundation, Incorporated | Compounds that modulate anti-tumor immunity and methods of doing the same |
| CN116710072A (zh) * | 2020-11-03 | 2023-09-05 | 基石制药股份有限公司 | 使用德维司他治疗胆道癌的治疗方法和组合物 |
| CN119770650A (zh) * | 2025-01-09 | 2025-04-08 | 华中科技大学 | 一种硫辛酸-胆碱离子液体溶液及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2805251A (en) * | 1953-07-22 | 1957-09-03 | Ethyl Corp | Preparation of aryloxyaliphatic acids and salts thereof |
| GB758897A (en) | 1953-10-19 | 1956-10-10 | Merck & Co Inc | Thio-substituted aliphatic carboxylic acids and their preparation |
| US2809978A (en) * | 1953-12-04 | 1957-10-15 | Merck & Co Inc | Intermediates useful in the synthesis of alpha-lipoic acid |
| US3002011A (en) * | 1953-12-04 | 1961-09-26 | Merck & Co Inc | Intermediates and processes for producing alpha-lipoic acid |
| US2980716A (en) * | 1954-06-11 | 1961-04-18 | Research Corp | Method for preparing 6, 8-dihalooctanoic esters |
| US2975198A (en) * | 1954-07-08 | 1961-03-14 | Research Corp | Lipoic acid intermediates |
| US2852531A (en) * | 1954-09-24 | 1958-09-16 | Merck & Co Inc | Tris-(2-tetrahydropyranyl) esters of 6, 8-bis (hydrocarbonmercapto)-4, 4-dicarboxy-5-ocaprylic acid and preparation thereof |
| US2875238A (en) * | 1957-02-19 | 1959-02-24 | Merck & Co Inc | Intermediates useful in the synthesis of alpha-lipoic acid |
| US2875239A (en) * | 1957-02-19 | 1959-02-24 | Merck & Co Inc | Intermediates useful in the synthesis of alpha-lipoic acid |
| US2985685A (en) * | 1959-01-26 | 1961-05-23 | American Cyanamid Co | Alkanolamine aluminates as catalysts for ester redistribution |
| US3453312A (en) * | 1966-04-27 | 1969-07-01 | Merck & Co Inc | (beta - (substituted-thio) - acylphenoxy)-alkanoic acids and (beta-(substitutedthio) acylphenylmercapto) alkanoic acids and derivatives thereof |
| US3345368A (en) * | 1967-02-15 | 1967-10-03 | American Cyanamid Co | Substituted 7-acetylamino cephalosporanic acids |
| US3881017A (en) * | 1973-05-18 | 1975-04-29 | Ciba Geigy Corp | 9-Thiaprostaglandin compositions |
| DE2422498A1 (de) * | 1973-05-18 | 1974-12-05 | Ciba Geigy Ag | Neue thiaprostaglandine und verfahren zu ihrer herstellung |
| JPS5323539Y2 (cg-RX-API-DMAC7.html) * | 1973-11-30 | 1978-06-17 | ||
| DE3512911A1 (de) * | 1985-04-11 | 1986-10-16 | Degussa Ag, 6000 Frankfurt | Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure) |
| US5344941A (en) * | 1986-09-03 | 1994-09-06 | Samour Carlos M | Water soluble salts of thionaphthene-2-carboxylic acid |
| DE4000397A1 (de) * | 1990-01-09 | 1991-07-11 | Hoechst Ag | Lipidselektive antioxidantien sowie deren herstellung und verwendung |
| US5569670A (en) * | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
| WO1994023748A1 (en) * | 1993-04-08 | 1994-10-27 | The University Of Queensland | Administration of vaso-active agent and therapeutic agent |
| US5463093A (en) * | 1993-11-26 | 1995-10-31 | Garnett; Merrill | Palladium complexes and methods for using same in the treatment of tumors or Psoriasis |
| FR2777001B1 (fr) * | 1998-04-01 | 2000-06-09 | Cird Galderma | Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses |
| IL142824A0 (en) * | 1998-10-26 | 2002-03-10 | Univ New York State Res Found | Lipoic acid derivatives and their use in treatment of disease |
| US7320797B2 (en) * | 2003-08-29 | 2008-01-22 | Bioderm Research | Antiaging cosmetic delivery systems |
| JP2007077066A (ja) * | 2005-09-14 | 2007-03-29 | Shiseido Co Ltd | 不全角化抑制剤、毛穴縮小剤 |
| US20090036356A1 (en) * | 2006-03-06 | 2009-02-05 | Avestha Gengraine Technologies Pvt. Ltd. | Octanoic acid derivatives as dipeptidyl peptidase inhibitors |
| BRPI0810660A2 (pt) * | 2007-04-18 | 2014-10-07 | Cornerstone Pharmaceuticals Inc | Derivados do ácido lipóico |
| NZ580973A (en) | 2007-04-18 | 2011-10-28 | Cornerstone Pharmaceuticals Inc | Pharmaceutical formulations containing lipoic acid derivatives |
| US8263653B2 (en) * | 2007-04-18 | 2012-09-11 | Cornerstone Pharmaceuticals, Inc. | Pharmaceutical formulations containing lipoic acid derivatives |
-
2008
- 2008-04-17 NZ NZ580973A patent/NZ580973A/en not_active IP Right Cessation
- 2008-04-17 ES ES08780538.8T patent/ES2528414T3/es active Active
- 2008-04-17 AU AU2008242827A patent/AU2008242827B2/en not_active Ceased
- 2008-04-17 WO PCT/US2008/060650 patent/WO2008131114A2/en not_active Ceased
- 2008-04-17 MX MX2009011165A patent/MX2009011165A/es active IP Right Grant
- 2008-04-17 EP EP08780538.8A patent/EP2144609B1/en not_active Not-in-force
- 2008-04-17 CA CA2684479A patent/CA2684479C/en active Active
- 2008-04-17 KR KR1020097023900A patent/KR101539785B1/ko not_active Expired - Fee Related
- 2008-04-17 PT PT87805388T patent/PT2144609E/pt unknown
- 2008-04-17 JP JP2010504247A patent/JP5480804B2/ja not_active Expired - Fee Related
- 2008-04-17 CN CN200880017628.5A patent/CN101820875B/zh not_active Expired - Fee Related
- 2008-04-17 PL PL08780538T patent/PL2144609T3/pl unknown
- 2008-04-17 BR BRPI0810439-5A patent/BRPI0810439B1/pt not_active IP Right Cessation
- 2008-04-17 US US12/105,100 patent/US20080262077A1/en not_active Abandoned
- 2008-04-18 CL CL2008001124A patent/CL2008001124A1/es unknown
- 2008-04-18 TW TW097114308A patent/TWI459944B/zh not_active IP Right Cessation
- 2008-04-18 AR ARP080101607A patent/AR067309A1/es not_active Application Discontinuation
- 2008-04-19 SA SA08290240A patent/SA08290240B1/ar unknown
-
2009
- 2009-10-15 IL IL201581A patent/IL201581A/en active IP Right Grant
-
2011
- 2011-10-05 US US13/253,503 patent/US8691873B2/en active Active
-
2014
- 2014-03-27 US US14/227,148 patent/US9320726B2/en not_active Expired - Fee Related
-
2016
- 2016-04-21 US US15/134,896 patent/US9872845B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008001124A1 (es) | Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. | |
| CL2009000393A1 (es) | Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular. | |
| CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| BR112015019432A2 (pt) | Compostos de tubulisina, métodos de produção e uso | |
| CU20120042A7 (es) | (heteroarilmetil)tiohidantoínas sustituidas como drogas anticáncer | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| MX2020002867A (es) | Inhibidores de glucosilceramida sintasa. | |
| CY1115254T1 (el) | Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις | |
| CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
| ECSP10010216A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| CL2016000379A1 (es) | Composiciones y métodos terapéuticos para reducción acelerada de plagas | |
| BR112016005252A2 (pt) | composto direcionado às proteínas poliposi coli adematosa (apc) truncadas, uso do mesmo e célula epitelial do cólon humana imortalizada (hcec) | |
| MX359209B (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| BR112012027393A2 (pt) | composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer |